This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Conference in headline and first graph, first sentence of release should read: Jefferies 2012 Global Healthcare Conference (sted 2011).
The corrected release reads:
LIGAND TO PRESENT AT THE JEFFERIES 2012 GLOBAL HEALTHCARE CONFERENCE ON JUNE 4Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer, and Matt Foehr, Executive Vice President and Chief Operating Officer, will present at the Jefferies 2012 Global Healthcare Conference on Monday, June 4, 2012 at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). The conference takes place at the Grand Hyatt New York in New York City.
A live webcast of the presentation will be available on the Company’s website
www.ligand.com. A replay of the presentation will be archived on the site for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., The Medicines Company, Curis, Inc. and Rib-X Pharmaceuticals. Please visit
www.captisol.com for more information on Captisol. For more information on Ligand, please visit
Follow Ligand on Twitter @Ligand_LGND.